Drugs / GLPG1837
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02562859 | Sep → Oct 2015 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02562950 | Sep → Oct 2015 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02325037 | Dec 2014 → Sep 2015 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT02707562 | Feb → Nov 2016 | cystic fibrosis | Lakefront Biotherapeutics NV | Completed | Met primary |
| Phase 2 | NCT02690519 | Jan → Aug 2016 | cystic fibrosis | Lakefront Biotherapeutics NV | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2016-12-20 | Lakefront Biotherapeutics NV | Results SAPHIRA 1 topline shows competitive clinical results in G551D patients lakefrontbio.com ↗
Galapagos NV (Euronext & NASDAQ: GLPG) reports topline results from its SAPHIRA 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837. |
| 2016-10-27 | Lakefront Biotherapeutics NV | Results Galapagos to present progress in CF programs at NACFC 2016 lakefrontbio.com ↗
Galapagos and AbbVie present the development of assays using patient-derived organoids and the data obtained using GLPG1837 across assays. |
| 2016-01-19 | Lakefront Biotherapeutics NV | Regulatory Galapagos advances CF clinical development lakefrontbio.com ↗
Galapagos has made regulatory filings for exploratory Phase 2 studies in CF patients for potentiator GLPG1837, and has received the first approvals to start from a number of countries. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-12-20 | Lakefront Biotherapeutics NV | SAPHIRA 1 topline shows competitive clinical results in G551D patients lakefrontbio.com ↗ |
| 2016-10-27 | Lakefront Biotherapeutics NV | Galapagos to present progress in CF programs at NACFC 2016 lakefrontbio.com ↗ |
| 2016-02-16 | Lakefront Biotherapeutics NV | Galapagos starts SAPHIRA Phase 2 study with GLPG1837 in cystic fibrosis patients lakefrontbio.com ↗ |
| 2016-01-19 | Lakefront Biotherapeutics NV | Galapagos advances CF clinical development lakefrontbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG1837 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02690519 ↗ |
| Action | Activate | “results show that GLPG1837 increases CFTR activity in G551D-CF patients” PMID 31147302 ↗ May 2019 |
| Route | Oral | “Single dose, oral suspension” NCT02325037 ↗ |
| Target | CFTR | “GLPG1837, a CFTR potentiator” PMID 31147302 ↗ May 2019 |